All patients
Age < 65y (younger) Age > 65y dMMR ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1% RAS mutant RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
colorectal cancer (CRC), atezolizumab based treatment vs. VEGF(R) inhibitor, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results AtezoTRIBE, 2022 0.66 [0.36; 1.19]
IMblaze-370 (A ; all population), 2019 1.00 [0.73; 1.37]
IMblaze-370 (AC ; all population), 2019 1.00 [0.73; 1.37]
0.95 [0.77 ; 1.17 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 0% 671 moderate not evaluable progression or deaths (PFS)detailed results AtezoTRIBE, 2022 0.69 [0.56; 0.85]
IMblaze-370 (A ; all population), 2019 1.39 [1.00; 1.94]
IMblaze-370 (AC ; all population), 2019 1.25 [0.94; 1.66]
1.05 [0.66 ; 1.67 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 89% 671 moderate not evaluable objective responses (ORR)detailed results AtezoTRIBE, 2022 0.78 [0.53; 1.14]
IMblaze-370 (A ; all population), 2019 1.00 [0.14; 7.26]
IMblaze-370 (AC ; all population), 2019 1.24 [0.24; 6.50]
0.80 [0.56 ; 1.16 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 0% 671 moderate not evaluable objective responses (ORR) (extension)detailed results AtezoTRIBE, 2022 0.77 [0.44; 1.36]
0.77 [0.44 ; 1.36 ] AtezoTRIBE, 2022 1 0% 218 NA not evaluable AE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.62 [0.18; 2.22]
IMblaze-370 (AC ; all population), 2019 1.52 [0.42; 5.53]
0.96 [0.39 ; 2.38 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable AE (grade 3-4)detailed results AtezoTRIBE, 2022 1.29 [0.71; 2.32]
IMblaze-370 (A ; all population), 2019 0.33 [0.18; 0.63]
IMblaze-370 (AC ; all population), 2019 1.15 [0.67; 1.97]
0.80 [0.35 ; 1.80 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 83% 643 moderate not evaluable AE leading to death (grade 5)detailed results AtezoTRIBE, 2022 2.03 [0.09; 45.56]
IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
IMblaze-370 (AC ; all population), 2019 1.12 [0.21; 5.90]
0.93 [0.25 ; 3.49 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 0% 647 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results AtezoTRIBE, 2022 3.09 [0.15; 62.46]
IMblaze-370 (A ; all population), 2019 0.49 [0.14; 1.72]
IMblaze-370 (AC ; all population), 2019 2.72 [1.15; 6.39]
1.43 [0.38 ; 5.40 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 60% 643 moderate not evaluable SAE (any grade)detailed results AtezoTRIBE, 2022 1.06 [0.56; 2.00]
IMblaze-370 (A ; all population), 2019 0.69 [0.32; 1.48]
IMblaze-370 (AC ; all population), 2019 2.26 [1.24; 4.14]
1.22 [0.61 ; 2.41 ] AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 3 68% 643 moderate not evaluable STRAE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.67 [0.24; 1.88]
IMblaze-370 (AC ; all population), 2019 2.73 [1.26; 5.89]
1.41 [0.35 ; 5.60 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 78% 429 moderate not evaluable TRAE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.05 [0.01; 0.16]
IMblaze-370 (AC ; all population), 2019 0.74 [0.19; 2.79]
0.18 [0.01 ; 2.73 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 89% 429 moderate not evaluable TRAE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.12 [0.05; 0.26]
IMblaze-370 (AC ; all population), 2019 0.85 [0.50; 1.44]
0.32 [0.05 ; 2.26 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 94% 429 moderate not evaluable TRAE leading to death (grade 5)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99]
0.71 [0.10 ; 5.06 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99]
0.89 [0.08 ; 9.99 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.05; 14.43]
IMblaze-370 (AC ; all population), 2019 1.81 [0.20; 16.42]
1.37 [0.24 ; 7.75 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 3.61 [0.16; 81.33]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
1.61 [0.14 ; 18.49 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.19 [0.26; 5.50]
IMblaze-370 (AC ; all population), 2019 0.29 [0.05; 1.77]
0.64 [0.16 ; 2.54 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 27% 429 moderate not evaluable Acute kidney injury AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Anaemia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
IMblaze-370 (AC ; all population), 2019 2.31 [0.49; 10.78]
1.06 [0.12 ; 9.33 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 44% 429 moderate not evaluable Arthralgia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.31 [0.03 ; 3.47 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Asthenia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.80 [0.16; 20.18]
IMblaze-370 (AC ; all population), 2019 3.22 [0.39; 26.58]
2.50 [0.51 ; 12.27 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Back pain AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 5.48 [0.27; 111.16]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
2.17 [0.20 ; 23.63 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Colitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.79 [0.18 ; 17.83 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Constipation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Cough AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19]
0.36 [0.07 ; 1.91 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Dermatitis acneiform AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.37 [0.12 ; 15.71 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.17 [0.02; 1.47]
IMblaze-370 (AC ; all population), 2019 1.89 [0.68; 5.22]
0.69 [0.07 ; 7.10 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 74% 429 moderate not evaluable Dysgeusia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Dysphonia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Fatigue AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.61 [0.19; 2.02]
IMblaze-370 (AC ; all population), 2019 0.49 [0.17; 1.40]
0.54 [0.25 ; 1.19 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Guillain-Barré syndrome AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Headache AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Hypertension AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.24 [0.06; 0.91]
IMblaze-370 (AC ; all population), 2019 0.08 [0.02; 0.37]
0.15 [0.05 ; 0.44 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 13% 429 moderate not evaluable Increased ALT AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.31 [0.03 ; 3.47 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.37 [0.12 ; 15.71 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Intestinal perforation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.31 [0.03 ; 3.47 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.37 [0.12 ; 15.71 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Myalgia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.31 [0.03 ; 3.47 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Nausea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.37 [0.12 ; 15.71 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.04 [0.00; 0.77]
IMblaze-370 (AC ; all population), 2019 0.02 [0.00; 0.39]
0.03 [0.00 ; 0.24 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.31 [0.03 ; 3.47 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Peripheral oedema AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.37 [0.12 ; 15.71 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Pneumonitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
1.26 [0.11 ; 14.04 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Pruritus AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Pyrexia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 6.47 [0.36; 115.44]
3.23 [0.32 ; 33.03 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Rash AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.04; 4.93]
IMblaze-370 (AC ; all population), 2019 1.59 [0.32; 7.82]
1.08 [0.28 ; 4.07 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Rash maculopapular AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
IMblaze-370 (AC ; all population), 2019 0.44 [0.03; 7.19]
0.44 [0.05 ; 3.83 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Sepsis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19]
0.36 [0.07 ; 1.91 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Stomatitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Vomiting AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.07 ; 11.69 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable Weight decreased AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.63 [0.04 ; 10.13 ] IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019 2 0% 429 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 22:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 126,385,183,384,137,138
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866